Contact Persons in Project 6: Acute Lymphoblastic Leukemia (ALL)

Created by: Gökbuget (ELIC/Project 6) , generated 2006/03/14, last changed: 2008/06/04

Name	Initials	Clinic	Country
Lead Participants
R. Bassan	BAS	Azienda Ospedaliera-Ospedali Riuniti di Bergamo	Italy
H. Dombret	DOM	Association Publique-Hôpitaux de Paris	France
R. Foa	FOA	Dipartimento di Biotecnologie Cellulari ed Ematologia, Università degli Studi di Roma "La Sapienza"	Italy
N. Gökbuget *	GOE	Universitätsklinikum Frankfurt	Germany
D. Hoelzer	HOE	Universitätsklinikum Frankfurt	Germany
J.M. Ribera	RIB	Insitut Català d'Oncologia-Hospital Universitari Germans Trias i Pujol	Spain
R. Willemze	WILL	Leiden University Medical Center	Netherlands
Participants
A. Dekker	DEK	University Medical Center Utrecht	Netherlands
M. Doubek		University Hospital Brno, Dept. of Internal Medicine - Hematooncology	Czech Republic
A. Fielding *	FIE		UK
S. Giebel		Silesian Medical Academy	Poland
A. Goldstone	GOL		UK
H. Hallböck	HALL		Sweden
J. Holowiecki		Silesian Medical Academy	Poland
N. Ifrah	IFR	Centre Hospitalier Universitaire d´Angers	France
B. Labar	LAB	University Hospital Center, Rebro	Croatia
F. Mandelli	MAN	Dipartimento di Biotecnologie Cellulari ed Ematologia, Università degli Studi di Roma "La Sapienza"	Italy
G. Martinelli		Institute of Hematology and Medical Oncology "Lorenzo e Ariosto Seràgnoli" University of Bologna	Italy
J. Mayer		The Brno Faculty Hospital, Department of Internal Medicine, Hematooncology	Czech Republic
G. Meloni	MEL	Dipartimento di Biotecnologie Cellulari ed Ematologia, Università degli Studi di Roma "La Sapienza"	Italy
J.M. Miclea		Institut Universitaire d`Hématologie, Hôpital St. Louis	France
A.D. Moicean *		Fundeni University Institute, Center of Hematology and Bone Marrow Transplantation	Romania
B. Ostrowska *		Centrum Onkologii-Instytut im. Marii Sklodowskiej-Curie Klinika Nowotworów Ukladn Chlonnego, Oddzial Intensywnej Opieki Hematoonkologicznej	Poland
O.G. Ottmann		Klinikum der J.W. Goethe Universität, Medizinische Klinik II	Germany
P.P. Piccaluga	PPP	Istituto di Ematologia e Oncologia Medica "L. e A. Seràgnoli"	Italy
S.J. Proctor		University of Newcastle, Haematological Sciences School of Clinical + Laboratory Sciences, Medical School	UK
P. Rousselot		Institut Universitaire d`Hématologie, Hôpital St. Louis	France
J.P. Vernant		Assistance Publique-Hôpitaux de Paris, Institut Universitaire d`Hematologie Hopital St. Louis,	France
M. Vignetti	VIG		Italy
J. Walewski		The Maria Sklodowska-Curie Memorial Cancer Center Institute of Oncology	Poland
* = Female Researcher

Lead Participants:

Dr. R. Bassan (Bergamo, Italy): Senior Consultant in Hematology, Ospedali Riuniti, Bergamo. Associate Professor of Hematology, University Milano-Bicocca. Main coordinator and promoter of Northern Italy Leukemia Group (NILG). Responsible for treatment protocol design and study conduct in adult ALL and AML, involving risk stratification according to disease immunophenotype, cytogenetics/molecular genetics, and risk-specific treatment allocation with/without stem cell transplantation. Leading an innovative minimal residual disease (MRD)-oriented study in ALL, and highly interested/ developing new studies in the field of supportive/anti-infection strategy, STI571 plus chemotherapy in Ph+ ALL, multidrug resistant and primary refractory leukemia, autologous blood stem cells, and optimal use of anthracyclinic drugs.

Prof.Dr. H. Dombret (Paris, France): Professor of Clinical Hematology, Hôpital Saint-Louis since 1996. Chairman of the Acute Leukemia French Association (ALFA). Co- chairman of the French GET-LALA Group (Groupe d'Etudes et de Traitement des Leucémies Aiguës Lymphoblastiques de l'Adulte). Longstanding experience in the organisation of clinical studies and therapeutical trials in acute and chronic leukemias, with a special interest in differentiation and pro-apoptotic therapies.

Prof.Dr. R. Foa (Rome, Italy):

Dr. N. Gökbuget (Frankfurt, Germany): Coordinator of the German Multicenter Studies for Adult ALL, Head of the German Leukemia Information Center, Head of the Study Center at the Medical Clinic III. Longstanding experience in planning, organisation and analysis of clinical multicenter trials (phase II-IV). Clinical studies in adult ALL including new cytostatic drugs or biologic approaches. Prognostic factors including molecular markers and their clinical application. Education and spread of excellence.

Prof.Dr. D. Hoelzer (Frankfurt, Germany): Professor of Medicine, Hematology/Oncology. Director of the Dept. of Hematology/Oncology. President of the European Hematology Association. Longstanding experience in research in hematology / adult ALL. Chairman of the German Multicenter Study Group for Adult ALL (GMALL) with 6 consecutive studies for adult de novo ALL and additional studies on mature B-ALL, Burkitt’s NHL, T-LBL, elderly patients, Ph/BCR-ABL positive ALL and relapsed ALL. The group has more than 100 participating centers and more than 3000 prospectively treated adult ALL patients.

Prof.Dr. J.M. Ribera (Barcelona, Spain): Chief of Clinical Hematology Service. Institut Català d’Oncologia- Hospital Universitari Germans Trias I Pujol, Badalona, Barcelona, Spain. Executive Secretary of PETHEMA (Programa de Estudio y Tratamiento de las Hemopatías Malignas, Spanish Society of Hematology) and Chairman of the Subcommittee of ALL. Chairman of the Subcommittee of ALL of GETH (Grupo Español de Trasplante Hemopoyético). Longstanding experience in design of protocols and clinical trials for treatment of children and adult acute lymphoblastic leukemia (ALL). Identification of prognostic markers in ALL, with a particular interest in adult ALL.

Prof.Dr. R. Willemze (Leiden, Netherlands):

Participants:

A. Dekker (Utrecht, Netherlands): Senior staff member Department of Hematology, University Medical Center Utrecht. Longstanding experience and interest in the prevention of infections in the immuno- compromised host; particularly in patients undergoing stemcell transplantation.

Dr. M. Doubek (Brno, Czech Republic):

A. Fielding (, UK):

Dr. S. Giebel (Katowice, Poland):

A. Goldstone (, UK):

H. Hallböck (, Sweden):

Prof.Dr. J. Holowiecki (Katowice, Poland):

Prof.Dr. N. Ifrah (Angers, France): Professor of Hematology, Angers University and Department of Hematology, Centre Hospitalier Universitaire. Responsible for coordination in clinical and biological studies. Longstanding experience in clinical and therapeutic trials in acute leukemias and bone marrow transplantation, with special interest in ALL. In this field, participation in identification of molecular and prognostic markers. Chairman of ALL projects in the French GOELAMS Network (Groupe Ouest-Est pour les Leucémies et Autres Maladies du Sang).

Prof.Dr. B. Labar (Zagreb, Croatia): Professor of Medicine at School of Medicine, University of Zagreb; Head of Division of Hematology, Clinical Hospital Center Zagreb. Coordinator of ALL protocols of EORTC. Chairman of Croatian Society of Hematology from 1995–1999, since 1999 coordinator of National Croatian Group for diagnosis and treatment of hematologic diseases. Research interest: Therapy of acute and chronic leukemia, autologous and allogeneic stem cell transplantation and immunotherapy.

Prof.Dr. F. Mandelli (Rome, Italy):

Prof.Dr. G. Martinelli (Bologna, Italy):

Dr. J. Mayer (Brno, Czech Republic):

Prof.Dr. G. Meloni (Rome, Italy): Associated Professor in Hematology, Università degli Studi La Sapienza, Roma. Head of the Autologous Transplantation Department. Specialist in Hematology and Pediatrics Research interest: Therapy of acute and chronic leukemia in adults and children, autologous stem cell transplantation in hematological malignancies in adults and children and immunotherapy.

Dr. J.M. Miclea (Paris, France):

Dr. A.D. Moicean (Bucharest, Romania):

Dr. B. Ostrowska (Warszawa, Poland):

PD Dr. O.G. Ottmann (Frankfurt am Main, Germany):

Dr. P.P. Piccaluga (Bologna, Italy): Researcher at the University of Bologna; Responsible for the Laboratory of Molecular Diagnostics and Therapy, Hematopathology Unit, Institute of Haematology and Medical Oncology “L. and A. Seràgnoli”. Special interests: clinical studies in acute leukemias (including new cytostatic drugs and biologic approaches); molecular biology of lymphoid malignancies.

Prof.Dr. S.J. Proctor (Newcastle upon Tyne, UK):

Dr. P. Rousselot (Paris, France):

Dr. J.P. Vernant (Paris, France):

M. Vignetti (, Italy):

Dr. J. Walewski (Warszaw, Poland): Consultant and lecturer in Medical Oncology, Head Department of Hemato-Oncology Intensive Care and Bone Marrow Transplantation Unit (EBMT CIC 800), Vice Chairman, Institutional Review Board for Therapeutic Policies, Member, Ethical Committee, Maria Sklodowska-Curie Memorial Cancer Center–Institute of Oncology. Co-Chairman, Polish Lymphoma Research Group.